Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma

Authors

Hervé Tilly, University of Rouen
Neha Mehta-Shah, Washington University School of Medicine in St. Louis
et al

Journal

New England Journal of Medicine

Publication Date

12-14-2021

Volume

386

Issue

4

First Page

351

Last Page

363

Document Type

Open Access Publication

DOI

10.1056/NEJMoa2115304

Rights and Permissions

Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers CR, Salles G. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022 Jan 27;386(4):351-363. doi: 10.1056/NEJMoa2115304 Copyright © 2021 Massachusetts Medical Society. Reprinted with permission.

Recommended Citation

Tilly, Hervé; Mehta-Shah, Neha; and et al, "Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma." New England Journal of Medicine. 386, 4. 351 - 363. (2021).
https://digitalcommons.wustl.edu/open_access_pubs/12038